Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | 2C7H6N2.4Cl.Ru |
| Molecular Weight | 479.15 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | -1 |
SHOW SMILES / InChI
SMILES
[Cl-].[Cl-].[Cl-].[Cl-].[Ru+3].N1N=CC2=C1C=CC=C2.N3N=CC4=C3C=CC=C4
InChI
InChIKey=ZKDYYHNSQGEUIA-UHFFFAOYSA-J
InChI=1S/2C7H6N2.4ClH.Ru/c2*1-2-4-7-6(3-1)5-8-9-7;;;;;/h2*1-5H,(H,8,9);4*1H;/q;;;;;;+3/p-4
| Molecular Formula | C7H6N2 |
| Molecular Weight | 118.1359 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | Ru |
| Molecular Weight | 101.07 |
| Charge | 3 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: G2/M cell cycle arrest Sources: https://www.medchemexpress.com/nkp-1339.html |
|||
Target ID: GO:0090592 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Characterizing activation mechanisms and binding preferences of ruthenium metallo-prodrugs by a competitive binding assay. | 2017-12 |
|
| Electronic State of Sodium trans-[Tetrachloridobis(1H-indazole)ruthenate(III)] (NKP-1339) in Tumor, Liver and Kidney Tissue of a SW480-bearing Mouse. | 2017-01-23 |
|
| Water-soluble Ru(II)- and Ru(III)-halide-PTA complexes (PTA=1,3,5-triaza-7-phosphaadamantane): Chemical and biological properties. | 2016-07 |
|
| X-ray Structure Analysis of Indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019) Bound to Human Serum Albumin Reveals Two Ruthenium Binding Sites and Provides Insights into the Drug Binding Mechanism. | 2016-06-23 |
|
| Molecular mode of action of NKP-1339 - a clinically investigated ruthenium-based drug - involves ER- and ROS-related effects in colon carcinoma cell lines. | 2016-06 |
|
| CF3 Derivatives of the Anticancer Ru(III) Complexes KP1019, NKP-1339, and Their Imidazole and Pyridine Analogues Show Enhanced Lipophilicity, Albumin Interactions, and Cytotoxicity. | 2016-05-16 |
|
| Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: a first-in-human, open-label, dose-escalation phase I study with expansion cohort. | 2016 |
|
| Improved reaction conditions for the synthesis of new NKP-1339 derivatives and preliminary investigations on their anticancer potential. | 2015-01-14 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Apr 01 21:52:22 GMT 2025
by
admin
on
Tue Apr 01 21:52:22 GMT 2025
|
| Record UNII |
74O61G9ZUO
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
189556-38-5
Created by
admin on Tue Apr 01 21:52:22 GMT 2025 , Edited by admin on Tue Apr 01 21:52:22 GMT 2025
|
PRIMARY | |||
|
300000056983
Created by
admin on Tue Apr 01 21:52:22 GMT 2025 , Edited by admin on Tue Apr 01 21:52:22 GMT 2025
|
PRIMARY | |||
|
74O61G9ZUO
Created by
admin on Tue Apr 01 21:52:22 GMT 2025 , Edited by admin on Tue Apr 01 21:52:22 GMT 2025
|
PRIMARY | |||
|
49787351
Created by
admin on Tue Apr 01 21:52:22 GMT 2025 , Edited by admin on Tue Apr 01 21:52:22 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
IONIC MOIETY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |